公开(公告)号：US20230357211A1

公开(公告)日：2023-11-09

申请号：US18245039

申请日：2021-09-13

Applicant: Pfizer Inc.

Inventor： Wesley Dewitt CLARK ,  Judith Gail DEAL ,  Brian Matthew SAMAS

IPC: C07D405/14

CPC classification number: C07D405/14 ,  C07B2200/13

Abstract: This invention relates to crystalline and amorphous forms of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.

公开(公告)号：US20210387989A1

公开(公告)日：2021-12-16

申请号：US17286018

申请日：2019-10-21

Applicant: Pfizer Inc.

Inventor： Brian Matthew SAMAS ,  Yong TAO ,  Douglas James Critcher ,  David Sydney Bernard Daniels ,  Kevin Paul Girard ,  Gregory Scott Goeken ,  Peter Robert Rose

IPC: C07D487/04

Abstract: The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof.